XOMA (NASDAQ:XOMA) Downgraded to “Sell” Rating by StockNews.com

StockNews.com lowered shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a research report report published on Tuesday.

Separately, HC Wainwright decreased their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a research note on Monday, February 3rd.

XOMA Trading Down 1.0 %

Shares of XOMA opened at $22.70 on Tuesday. XOMA has a 1 year low of $21.27 and a 1 year high of $35.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a 50 day simple moving average of $26.04 and a 200-day simple moving average of $27.92. The stock has a market cap of $267.47 million, a PE ratio of -6.52 and a beta of 0.90.

Insiders Place Their Bets

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Several institutional investors and hedge funds have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets grew its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares during the period. New York State Common Retirement Fund boosted its stake in XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 800 shares during the last quarter. Wells Fargo & Company MN grew its holdings in XOMA by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 1,183 shares during the period. Bank of America Corp DE raised its position in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,009 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of XOMA in the 4th quarter valued at $206,000. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.